Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patientsResults suggest tecovirimat provides clinical benefit vs. placebo in two important patient populations: those treated early and those with severe diseaseResults affirm tecovirimat’s strong safety profileMultiple additional clinical trials evaluating tecovirimat for mpox continue NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The Nation ...